REQUEST A DEMO
Total
USD $0.00
Search more companies

Zentiva Pharma D.O.O. (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Zentiva Pharma D.O.O. Profile Updated: September 30, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Zentiva Pharma D.O.O. is based in Serbia. The head office is in Belgrade. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. It was first established on February 04, 2010. There are currently 40 (2024) people employed by Zentiva Pharma D.O.O.. In 2024, the company reported a net sales revenue increase of 10.71%. Its total assets decreased by 5.25% over the same period. Zentiva Pharma D.O.O.’s net profit margin increased by 2.34% in 2024.

Headquarters
Milentija Popovica 5 V
Belgrade; Belgrade;

Contact Details: Purchase the Zentiva Pharma D.O.O. report to view the information.

Website: http://www.zentiva.rs

Basic Information
Total Employees:
Purchase the Zentiva Pharma D.O.O. report to view the information.
Registered Capital:
Purchase the Zentiva Pharma D.O.O. report to view the information.
Financial Auditors:
Purchase the Zentiva Pharma D.O.O. report to view the information.
Incorporation Date:
February 04, 2010
Key Executives
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Zentiva Pharma Makedonija D.O.O.E.L. (North Macedonia)
Company Performance
Financial values in the chart are available after Zentiva Pharma D.O.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
10.71%
Total operating revenue
10.71%
Operating profit (EBIT)
54.63%
EBITDA
41.32%
Net Profit (Loss) for the Period
150.37%
Total Assets
-5.25%
Total Equity
30.32%
Operating Profit Margin (ROS)
1.82%
Net Profit Margin
2.34%
Return on Equity (ROE)
11.16%
Debt/Equity
-128.96%
Quick Ratio
0.29%
Cash Ratio
0.02%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?